Insulet (PODD)
(Delayed Data from NSDQ)
$194.38 USD
-2.38 (-1.21%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $194.51 +0.13 (0.07%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PODD 194.38 -2.38(-1.21%)
Will PODD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PODD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PODD
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View
PODD: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy
Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand
ESLOY vs. PODD: Which Stock Is the Better Value Option?
Other News for PODD
A Closer Look at 7 Analyst Recommendations For Insulet
Insulet’s Growth Prospects Bolstered by AID Technology and Strategic Market Expansion
Healthcare 2024 Second Half Outlook
$1000 Invested In This Stock 15 Years Ago Would Be Worth $26,000 Today
CereVasc Announces Appointments of New Directors